1Semba RD, Najjar SS, Sun K, et al. Serum carboxymethyl -lysine, an advanced glycation end product,is associated with increased aortic pulse wave velocity in adults [ J]. Am J Hypertens ,2009,22( 1 ) :74 -79.
2Semba RD, Ferrucei L, Sun K, et al. Advanced glycation end prod- ucts and their circulating receptors predict cardiovascular disease mor- tality in older community - dwelling women[ J]. Aging Clin Exp Res, 2009, 21(2) :182 - 190.
3Rautureau Y, Paradis P, Schiffrin EL. Cross - talk between aldoste- rone and angiotensin signaling in vascular smooth muscle cell [ J ]. Steroids, 2011, 76(9):834-839.
4Savoia C, D'Agostino M, Lauri F, et al. Angiotensin type 2 receptor in hypertensive cardiovascular disease[J]. Curr Opin Nephrol Hyper- tens, 2011, 20(2) :125 -132.
5Frostegard J. Immunity, atherosclerosis and cardiovascular disease [J].BMC Med, 2013, 11(1):117.
6Ceausu M, Curaca C, Dermengiu D, et al. Simultaneous immunophe- notypical assessment of troponin and extracellular matrix molecules in myocardium of patients with suden cardiac death [ J]. Rom J Morphol Embryol, 2009, 50 ( 1 ) : 103 - 106.
7Mocatta TJ, Pilbrow AP. Cameron VA, et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction [J]. J Am Coil Cardiol, 2007, 49 (20) : 1993 - 2000.
8Lutgens E, Lievens D, Beckers L, et al. CD 40 and its ligand in ath- erosclerosis[ J]. Trends Cardiovasc Med, 2007, 17(4) :118 -123.
9Prondzinsky R, Unverzagt S, Lemm H, et al. Acute myocardial in- farction and cardiogenic shock : prognostic impact of cytokines : IFN - γ ,TNF- α ,MIP - 1β, G - CSF, and MCP -1β[J]. Medklin In- tensivmed Notfmed, 2012,107 (6) :476 - 484.
2Roberts R. PCSK9 inhibition-a new thrust in the prevention ofheart disease:genetics does it again[J]. Can J Cardiol,2013,29(8):899-901.
3Xu RX,Li S,Zhang Y,et al. Relation of plasma PCSK9 levelsto lipoprotein subfractions in patients with stable coronaryartery disease[j]. Lipids Health Dis,2014,13 : 188-204.
4Abifadel M,Guerin M, Benjannet S, et al. Identification andcharacterization of new gain-of-function mutations in thePCSK9 gene responsible for autosomal dominanthypercholesterolemia[ JD. Atherosclerosis, 2012,223 ( 2) : 394-400.
5Kosenko T, Golder M, Leblond G,et al. Low densitylipoprotein binds to proprotein convertase subtilisin/kexintype-9 (PCSK9) in human plasma and inhibits PCSK9-mediatedlow density lipoprotein receptor degradation[J]. J Biol Chem,2013,288(12):8279-8288.
6Leren TP. Sorting an LDL receptor with bound PCSK9 tointracellular degradation[J], Atherosclerosis, 2014,237(1) :76-81.
7Araki S,Suga S,Miyake F,et al. Circulating PCSK9 levelscorrelate with the serum LDL cholesterol level in newborninfants[J]_ Early Hum Dev,2014,90(10) :607-611.
8Kwakernaak AJ, Lambert G,Dullaart RP. Plasma proproteinconvertase subtilisin-kexin type 9 is predominantly related tointermediate density lipoproteins [J]. Clin Biochem, 2014, 47(7/8):679-682.
9Werner C,Hoffmann MM, Winkler K, et al. Risk predictionwith proprotein convertase subtilisin/kexin type 9 (PCSK9)inpatients with stable coronary disease on statin treatment [J].Vase Pharmacol,2014,62(2) :94-102.
10Wu Q,Tang ZH,Peng J,et al. The dual behavior of PCSK9 inthe regulation of apoptosis is crucial in Alzheimer's diseaseprogression (Review)[J]. Biomed Rep,2014,2(2) : 167-171.
